The FDA and genomic tests--getting regulation right.
作者信息
Evans Barbara J, Burke Wylie, Jarvik Gail P
机构信息
From the Center for Biotechnology and Law, University of Houston Law Center, Houston (B.J.E.); and the Departments of Bioethics and Humanities (W.B.), Medicine (Medical Genetics) (G.P.J.), and Genome Sciences (G.P.J.), University of Washington, Seattle.
出版信息
N Engl J Med. 2015 Jun 4;372(23):2258-64. doi: 10.1056/NEJMsr1501194. Epub 2015 May 27.
Abstract
摘要
相似文献
1
The FDA and genomic tests--getting regulation right.
N Engl J Med. 2015 Jun 4;372(23):2258-64. doi: 10.1056/NEJMsr1501194. Epub 2015 May 27.
2
Genetic testing and FDA regulation: overregulation threatens the emergence of genomic medicine.
JAMA. 2015 Feb 17;313(7):669-70. doi: 10.1001/jama.2014.18145.
3
Cutting the Gordian helix--regulating genomic testing in the era of precision medicine.
N Engl J Med. 2015 Mar 26;372(13):1185-6. doi: 10.1056/NEJMp1501964. Epub 2015 Feb 17.
4
The FDA and genetic testing.
N Engl J Med. 2015 Jun 4;372(23):2273-4. doi: 10.1056/NEJMc1504604. Epub 2015 May 27.
5
In search of a coherent framework: options for FDA oversight of genetic tests.
Food Drug Law J. 2007;62(4):617-52.
6
23andMe and the FDA.
N Engl J Med. 2014 Mar 13;370(11):985-8. doi: 10.1056/NEJMp1316367. Epub 2014 Feb 12.
7
Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service.
JAMA. 2014 Feb 26;311(8):793-4. doi: 10.1001/jama.2014.148.
8
FDA moves to regulate thousands of diagnostic tests.
Am J Manag Care. 2014 Aug;20(11 Spec No.):E12.
9
Science and regulation. Regulating direct-to-consumer personal genome testing.
Science. 2010 Oct 8;330(6001):181-2. doi: 10.1126/science.1194006.
10
US urged to monitor some genetic tests.
Nature. 1997 Feb 6;385(6616):477. doi: 10.1038/385477a0.
引用本文的文献
1
Understanding Genetic Screening: Harnessing Health Information to Prevent Disease Risks.
Int J Med Sci. 2025 Jan 21;22(4):903-919. doi: 10.7150/ijms.101219. eCollection 2025.
2
Artificial intelligence and urology: ethical considerations for urologists and patients.
Nat Rev Urol. 2024 Jan;21(1):50-59. doi: 10.1038/s41585-023-00796-1. Epub 2023 Jul 31.
3
Polygenic Scores in the Direct-to-Consumer Setting: Challenges and Opportunities for a New Era in Consumer Genetic Testing.
J Pers Med. 2023 Mar 23;13(4):573. doi: 10.3390/jpm13040573.
4
Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements.
EPMA J. 2022 Nov 12;13(4):561-580. doi: 10.1007/s13167-022-00304-2. eCollection 2022 Dec.
5
Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes.
EPMA J. 2021 Oct 7;12(4):545-558. doi: 10.1007/s13167-021-00254-1. eCollection 2021 Dec.
6
Temporary Regulatory Deviations and the Coronavirus Disease 2019 (COVID-19) PCR Labeling Update Study Indicate What Laboratory-Developed Test Regulation by the US Food and Drug Administration (FDA) Could Look Like.
J Mol Diagn. 2021 Oct;23(10):1207-1217. doi: 10.1016/j.jmoldx.2021.07.011. Epub 2021 Sep 16.
7
The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case.
Curr Opin Lipidol. 2021 Apr 1;32(2):89-95. doi: 10.1097/MOL.0000000000000733.
8
Clinical metagenomics for infectious corneal ulcers: Rags to riches?
Ocul Surf. 2020 Jan;18(1):1-12. doi: 10.1016/j.jtos.2019.10.007. Epub 2019 Oct 25.
9
A decade of clinical development of PARP inhibitors in perspective.
Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192.
10
Developmental roadmap for antimicrobial susceptibility testing systems.
Nat Rev Microbiol. 2019 Jan;17(1):51-62. doi: 10.1038/s41579-018-0098-9.
本文引用的文献
1
A new initiative on precision medicine.
N Engl J Med. 2015 Feb 26;372(9):793-5. doi: 10.1056/NEJMp1500523. Epub 2015 Jan 30.
2
Genetic testing and FDA regulation: overregulation threatens the emergence of genomic medicine.
JAMA. 2015 Feb 17;313(7):669-70. doi: 10.1001/jama.2014.18145.
3
FDA regulation of laboratory-developed diagnostic tests: protect the public, advance the science.
JAMA. 2015 Feb 17;313(7):667-8. doi: 10.1001/jama.2014.18135.
4
Development of the clinical next-generation sequencing industry in a shifting policy climate.
Nat Biotechnol. 2014 Oct;32(10):980-2. doi: 10.1038/nbt.3030.
5
Clinical interpretation and implications of whole-genome sequencing.
JAMA. 2014 Mar 12;311(10):1035-45. doi: 10.1001/jama.2014.1717.
6
CLIA program and HIPAA privacy rule; patients' access to test reports. Final rule.
Fed Regist. 2014 Feb 6;79(25):7289-316.
7
Large numbers of individuals are required to classify and define risk for rare variants in known cancer risk genes.
Genet Med. 2014 Jul;16(7):529-34. doi: 10.1038/gim.2013.187. Epub 2013 Dec 19.
8
Actionable, pathogenic incidental findings in 1,000 participants' exomes.
Am J Hum Genet. 2013 Oct 3;93(4):631-40. doi: 10.1016/j.ajhg.2013.08.006. Epub 2013 Sep 19.
9
ACMG clinical laboratory standards for next-generation sequencing.
Genet Med. 2013 Sep;15(9):733-47. doi: 10.1038/gim.2013.92. Epub 2013 Jul 25.
10
Taxonomizing, sizing, and overcoming the incidentalome.
Genet Med. 2012 Apr;14(4):399-404. doi: 10.1038/gim.2011.68. Epub 2012 Feb 9.
Zotero 插件